辉瑞产品线
相关主题
- 1、下载文档前请自行甄别文档内容的完整性，平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益，请联系客服反馈,我们会尽快为您处理(人工客服工作时间：9:00-18:30)。
►Indicates that the project is either new or has progressed in phase since
the previous portfolio update of Pfizer.com
New Indication or Enhancement
Mechanism of Action
Rheumatoid Arthritis Crohn’s Disease, Lupus (Biologic) Ulcerative Colitis (Biologic) Dermal Scarring Ankylosing Spondylitis, Psoriasis (Topical), Crohn’s Disease, Atopic Dermatitis, RA (EU), *QD MR Rheumatoid Arthritis (Biologic) Chronic Obstructive Pulmonary Disease Lupus Psoriasis (Topical) Diabetes Mellitus-Type 1 (BiologiBaidu Nhomakorabea) Crohn's Disease (Biologic)
Therapeutic Area Compound Name Eliquis (apixaban) bococizumab (RN316 ) (PF04950615) ertugliflozin (PF-04971729) Cardiovascular and Metabolic Diseases PF-00489791 PF-04634817 PF-04937319 PF-05175157 PF-06282999 PF-06291874
(Phase 2 through regulatory approval)
Indication Chronic Pain (US) Severe Pain (US) Severe Pain Peripheral Neuropathic Pain CR (once a day dosing) OA Signs and Symptoms (on clinical hold) Huntington’s Disease – (ORPHAN – U.S.) Adjunctive Treatment for Schizophrenia Cerebral Amyloid Angiopathy (Biologic) Alzheimer’s Disease Cancer Pain (Biologic) Schizophrenia Chronic Pain Alzheimer’s Disease (Biologic) Chronic Pain Cognitive Disorder Parkinson's Disease Cognitive Disorder Gout
(Phase 2 through regulatory approval)
New Indication or Enhancement
Indication Psoriasis (Oral) Ulcerative Colitis Psoriatic Arthritis Sarcoidosis, *Lupus (Biologic)
5
New Molecular Entity
Pfizer Pipeline – August 7, 2014 (cont’d)
Therapeutic Area Compound Name Xeljanz (tofacitinib) Xeljanz (tofacitinib) Xeljanz (tofacitinib) PD-0360324 Mechanism of Action
Pfizer Pipeline – August 7, 2014 (cont’d)
Therapeutic Area Compound Name Celebrex Remoxy ALO-02 Oxycodonenaltrexone core Lyrica Lyrica tanezumab Neuroscience & Pain PF-02545920 PF-04360365 (ponezumab) PF-05212377 (SAM-760) tanezumab PF-04958242 PF-05089771 PF-05236812 (AAB-003) PF-06372865 PF-06412562 PF-06649751 ►PF-06669571 ►PF-06743649
Phase Registration Phase 3 Phase 3 Phase 2 Phase 2 Phase 2 Phase 2 Phase 1 Phase 1
Factor Xa Inhibitor PCSK9 Inhibitor SGLT-2 Inhibitor PDE5 Inhibitor CCR2/5 Antagonist Partial Glucokinase Activator Acetyl-CoA carboxylase Inhibitor
Pfizer Pipeline Snapshot as of May 8, 2014 Registration 6
Phase 2 23
Phase 3 20
Total 84
Pipeline represents progress of R&D programs as of May 8, 2014 Included are 62 NMEs, 17 additional indications, plus 5 biosimilars
MAdCAM Inhibitor
Selective Glucocorticoid Receptor Modulator IL-6 Inhibitor Multipotent Adult Progenitor Cell CTGF Inhibitor JAK Inhibitor
Crohn’s Disease, Ulcerative Colitis (Biologic)
2
Table of Contents
Pfizer Pipeline Snapshot Cardiovascular & Metabolic Diseases 4 5
Inflammation & Immunology
Neuroscience & Pain Oncology Rare Diseases Vaccines Other Areas of Focus
New Indication or Enhancement
Mechanism of Action
(Phase 2 through regulatory approval)
Indication Venous Thromboembolism Treatment (US) Treatment of Hyperlipidemia (Biologic) Diabetes Mellitus-Type 2 Diabetic Nephropathy Diabetic Nephropathy, Diabetic Macular Edema Diabetes Mellitus-Type 2 Diabetes Mellitus-Type 2 Acute Coronary Syndrome Diabetes Mellitus-Type 2
Discovery Projects Phase 1 34 4 programs advanced or are new Pfizer Pipeline Snapshot as of August 7, 2014
Phase 2 23
Phase 3 20
Registration 6
Total 83
Pipeline represents progress of R&D programs as of August 7, 2014 Included are 61 NMEs, 17 additional indications, plus 5 biosimilars
Phase 2
Phase 2 Phase 2 Phase 2 Phase 2 Phase 2 Phase 1 Phase 1 Phase 1 Phase 1 Phase 1 Phase 1
* Note: Additional indications in Phase 1
6
New Molecular Entity
4 projects discontinued since last update
Recent Approval - Eliquis for Venous Thromboembolism Treatment (EU)
Discovery Projects Phase 1 35
3 programs advanced or are new
● Visit Pfizer.com/pipeline, Pfizer’s online database where you can
learn more about our portfolio of new medicines and find out more about our Research and Development efforts around the world.
0 projects discontinued since last update
Recent Approval - Eliquis for Venous Thromboembolism Prevention (US)
4
New Molecular Entity
Pfizer Pipeline – August 7, 2014
Pfizer Pipeline
As of August 7, 2014
Disclaimer
● As some programs are still confidential, some candidates may not
be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA) information for candidates from Phase 2 through regulatory approval. With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant commercial opportunities. The information contained on these pages is correct as of August 7, 2014.
(including Biosimilars)
6
7 8 9 10 11 12 13-14
Projects Discontinued Since Last Update Backup: Regulatory Designation Definitions
3
Pfizer Pipeline Snapshot
Phase Phase 3 Phase 3 Phase 3 Phase 2
JAK Inhibitor JAK Inhibitor JAK Inhibitor M-CSF Inhibitor
PF-00547659
PF-04171327 PF-04236921 Inflammation and Immunology PF-05285401 PF-06473871 (EXC 001) Xeljanz (tofacitinib) Dekavil PF-03715455 PF-04965842 PF-06263276 PF-06342674 PF-06480605
the previous portfolio update of Pfizer.com
New Indication or Enhancement
Mechanism of Action
Rheumatoid Arthritis Crohn’s Disease, Lupus (Biologic) Ulcerative Colitis (Biologic) Dermal Scarring Ankylosing Spondylitis, Psoriasis (Topical), Crohn’s Disease, Atopic Dermatitis, RA (EU), *QD MR Rheumatoid Arthritis (Biologic) Chronic Obstructive Pulmonary Disease Lupus Psoriasis (Topical) Diabetes Mellitus-Type 1 (BiologiBaidu Nhomakorabea) Crohn's Disease (Biologic)
Therapeutic Area Compound Name Eliquis (apixaban) bococizumab (RN316 ) (PF04950615) ertugliflozin (PF-04971729) Cardiovascular and Metabolic Diseases PF-00489791 PF-04634817 PF-04937319 PF-05175157 PF-06282999 PF-06291874
(Phase 2 through regulatory approval)
Indication Chronic Pain (US) Severe Pain (US) Severe Pain Peripheral Neuropathic Pain CR (once a day dosing) OA Signs and Symptoms (on clinical hold) Huntington’s Disease – (ORPHAN – U.S.) Adjunctive Treatment for Schizophrenia Cerebral Amyloid Angiopathy (Biologic) Alzheimer’s Disease Cancer Pain (Biologic) Schizophrenia Chronic Pain Alzheimer’s Disease (Biologic) Chronic Pain Cognitive Disorder Parkinson's Disease Cognitive Disorder Gout
(Phase 2 through regulatory approval)
New Indication or Enhancement
Indication Psoriasis (Oral) Ulcerative Colitis Psoriatic Arthritis Sarcoidosis, *Lupus (Biologic)
5
New Molecular Entity
Pfizer Pipeline – August 7, 2014 (cont’d)
Therapeutic Area Compound Name Xeljanz (tofacitinib) Xeljanz (tofacitinib) Xeljanz (tofacitinib) PD-0360324 Mechanism of Action
Pfizer Pipeline – August 7, 2014 (cont’d)
Therapeutic Area Compound Name Celebrex Remoxy ALO-02 Oxycodonenaltrexone core Lyrica Lyrica tanezumab Neuroscience & Pain PF-02545920 PF-04360365 (ponezumab) PF-05212377 (SAM-760) tanezumab PF-04958242 PF-05089771 PF-05236812 (AAB-003) PF-06372865 PF-06412562 PF-06649751 ►PF-06669571 ►PF-06743649
Phase Registration Phase 3 Phase 3 Phase 2 Phase 2 Phase 2 Phase 2 Phase 1 Phase 1
Factor Xa Inhibitor PCSK9 Inhibitor SGLT-2 Inhibitor PDE5 Inhibitor CCR2/5 Antagonist Partial Glucokinase Activator Acetyl-CoA carboxylase Inhibitor
Pfizer Pipeline Snapshot as of May 8, 2014 Registration 6
Phase 2 23
Phase 3 20
Total 84
Pipeline represents progress of R&D programs as of May 8, 2014 Included are 62 NMEs, 17 additional indications, plus 5 biosimilars
MAdCAM Inhibitor
Selective Glucocorticoid Receptor Modulator IL-6 Inhibitor Multipotent Adult Progenitor Cell CTGF Inhibitor JAK Inhibitor
Crohn’s Disease, Ulcerative Colitis (Biologic)
2
Table of Contents
Pfizer Pipeline Snapshot Cardiovascular & Metabolic Diseases 4 5
Inflammation & Immunology
Neuroscience & Pain Oncology Rare Diseases Vaccines Other Areas of Focus
New Indication or Enhancement
Mechanism of Action
(Phase 2 through regulatory approval)
Indication Venous Thromboembolism Treatment (US) Treatment of Hyperlipidemia (Biologic) Diabetes Mellitus-Type 2 Diabetic Nephropathy Diabetic Nephropathy, Diabetic Macular Edema Diabetes Mellitus-Type 2 Diabetes Mellitus-Type 2 Acute Coronary Syndrome Diabetes Mellitus-Type 2
Discovery Projects Phase 1 34 4 programs advanced or are new Pfizer Pipeline Snapshot as of August 7, 2014
Phase 2 23
Phase 3 20
Registration 6
Total 83
Pipeline represents progress of R&D programs as of August 7, 2014 Included are 61 NMEs, 17 additional indications, plus 5 biosimilars
Phase 2
Phase 2 Phase 2 Phase 2 Phase 2 Phase 2 Phase 1 Phase 1 Phase 1 Phase 1 Phase 1 Phase 1
* Note: Additional indications in Phase 1
6
New Molecular Entity
4 projects discontinued since last update
Recent Approval - Eliquis for Venous Thromboembolism Treatment (EU)
Discovery Projects Phase 1 35
3 programs advanced or are new
● Visit Pfizer.com/pipeline, Pfizer’s online database where you can
learn more about our portfolio of new medicines and find out more about our Research and Development efforts around the world.
0 projects discontinued since last update
Recent Approval - Eliquis for Venous Thromboembolism Prevention (US)
4
New Molecular Entity
Pfizer Pipeline – August 7, 2014
Pfizer Pipeline
As of August 7, 2014
Disclaimer
● As some programs are still confidential, some candidates may not
be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA) information for candidates from Phase 2 through regulatory approval. With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant commercial opportunities. The information contained on these pages is correct as of August 7, 2014.
(including Biosimilars)
6
7 8 9 10 11 12 13-14
Projects Discontinued Since Last Update Backup: Regulatory Designation Definitions
3
Pfizer Pipeline Snapshot
Phase Phase 3 Phase 3 Phase 3 Phase 2
JAK Inhibitor JAK Inhibitor JAK Inhibitor M-CSF Inhibitor
PF-00547659
PF-04171327 PF-04236921 Inflammation and Immunology PF-05285401 PF-06473871 (EXC 001) Xeljanz (tofacitinib) Dekavil PF-03715455 PF-04965842 PF-06263276 PF-06342674 PF-06480605